CASI PHARMACEUTICALS INC (CASI)
KYG1933S1012 - Common Stock
Taking everything into account, CASI scores 3 out of 10 in our fundamental rating. CASI was compared to 588 industry peers in the Biotechnology industry. Both the profitability and financial health of CASI have multiple concerns. CASI is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CASI had negative earnings in the past year.
In the past year CASI has reported a negative cash flow from operations.
In the past 5 years CASI always reported negative net income.
CASI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
CASI has a better Return On Assets (-35.83%) than 65.24% of its industry peers.
CASI has a Return On Equity of -111.60%. This is comparable to the rest of the industry: CASI outperforms 42.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.83% | ||
| ROE | -111.6% | ||
| ROIC | N/A |
ROA(3y)-34.98%
ROA(5y)-37.53%
ROE(3y)-82.3%
ROE(5y)-73.84%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 59.17%, CASI belongs to the best of the industry, outperforming 81.16% of the companies in the same industry.
CASI's Gross Margin has improved in the last couple of years.
CASI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 59.17% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.76%
GM growth 5YN/A
2. Health
2.1 Basic Checks
CASI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CASI has been reduced compared to 1 year ago.
Compared to 5 years ago, CASI has more shares outstanding
The debt/assets ratio for CASI is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -11.89, we must say that CASI is in the distress zone and has some risk of bankruptcy.
CASI has a Altman-Z score of -11.89. This is in the lower half of the industry: CASI underperforms 79.11% of its industry peers.
A Debt/Equity ratio of 0.78 indicates that CASI is somewhat dependend on debt financing.
CASI has a worse Debt to Equity ratio (0.78) than 75.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.89 |
ROIC/WACCN/A
WACC6.75%
2.3 Liquidity
CASI has a Current Ratio of 3.55. This indicates that CASI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.55, CASI is doing worse than 60.45% of the companies in the same industry.
CASI has a Quick Ratio of 2.60. This indicates that CASI is financially healthy and has no problem in meeting its short term obligations.
CASI's Quick ratio of 2.60 is on the low side compared to the rest of the industry. CASI is outperformed by 69.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.55 | ||
| Quick Ratio | 2.6 |
3. Growth
3.1 Past
CASI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.59%, which is quite impressive.
Looking at the last year, CASI shows a very negative growth in Revenue. The Revenue has decreased by -21.38% in the last year.
CASI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 30.80% yearly.
EPS 1Y (TTM)40.59%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q75.81%
Revenue 1Y (TTM)-21.38%
Revenue growth 3Y30.8%
Revenue growth 5YN/A
Revenue growth Q2Q-54.95%
3.2 Future
CASI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.53% yearly.
The Revenue is expected to grow by 36.26% on average over the next years. This is a very strong growth
EPS Next Y100%
EPS Next 2Y18.92%
EPS Next 3Y32.92%
EPS Next 5Y21.53%
Revenue Next Year62.47%
Revenue Next 2Y56.48%
Revenue Next 3Y47.99%
Revenue Next 5Y36.26%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
CASI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CASI's earnings are expected to grow with 32.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.92%
EPS Next 3Y32.92%
5. Dividend
5.1 Amount
No dividends for CASI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CASI PHARMACEUTICALS INC
NASDAQ:CASI (4/23/2024, 7:00:01 PM)
After market: 2.42 -0.09 (-3.59%)2.51
+0.08 (+3.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap33.63M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.83% | ||
| ROE | -111.6% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 59.17% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.55 | ||
| Quick Ratio | 2.6 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)40.59%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y100%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-21.38%
Revenue growth 3Y30.8%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y